Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI +/- Bevacizumab in Unresectable Colorectal Liver-Limited Metastases
NCT02350530Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2015
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Conversion rate of liver metastases at 8 months. Started Jan 2015; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02350530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02350530.